IFNB1 and myeloid sarcoma: Different pathophysiologic mechanisms are known to characterize MS and NMOSD, a finding at least partially demonstrated by the fact that exacerbations can be precipitated by fingolimod, IFNβ and natalizumab, treatments that are effective in MS.